In Monday's Blitz Daily with Lance Ippolito, we take a look at pharmaceutical company Altamira Therapeutics after spotting some unusual options activity...
This tiny company specializes in developing therapeutics that address important, unmet medical needs. It’s currently working on RNA therapeutics as well as treatments for allergy and viral infections, and inner-ear disorders.
Altamira announced Monday that the International Journal of Molecular Sciences published a peer-reviewed paper confirming the safety and effectiveness of its Bentrio nasal spray for the COVID-19 Delta variant.
A separate study has already confirmed the nasal spray’s effectiveness against the omicron variant.
The positive news brought the bulls out in full force!
And that wasn’t the only ticker hitting the scanner…
Disclaimer : The material in this document is for informational purposes based on our proprietary research. It is not an offering, specific recommendation, or a solicitation of an offer to buy or sell any securities mentioned or discussed herein.
Any performance results discussed herein represent past performance, are not a guarantee of future performance, and are not indicative of any specific investment.
Due to the timing of information presented, any investment performance reflected within this document may be adjusted after the publication and distribution of this material. There can be no assurance that the future performance of any specific investment, investment strategy, or product made reference to directly or indirectly in this communication will be profitable, be equal to any corresponding indicated historical performance levels or be suitable for your portfolio. Any investment results set forth in this document are not net of expenses and execution costs, nor do they account for other relevant trading or investment fees. Please visit wealthpress.com/terms for our full Terms and Conditions.
0 Response to "CYTO’s Newest Coronavirus Treatment Sends Stock, Options Soaring"
Post a Comment